BACKGROUND: Sustained virological response (SVR) is achieved in a high proportion of patients with chronic hepatitis C infection, particularly those with genotype 2 or 3 HCV infection. However, data on long-term durability of virological response in patients who achieve SVR are limited. AIM: To evaluate the long-term durability of virological response in patients who have achieved SVR with interferon-based combination therapy. METHODS: One hundred patients with chronic HCV infection who had obtained SVR after IFN and ribavirin combination therapy were followed up for up to 8 years with annual HCV RNA testing. RESULTS: During a followed up of 6 months to 8 years, 8 of 100 patients with initial SVR developed late relapse of HCV infection. Relapse was more common in patients who had cirrhosis (5/28 [18%] vs. (3/72 [4%] with no cirrhosis; p=0.037). CONCLUSION: SVR is durable in most patients, but some patients do have late relapse; long term follow up may be particularly important in a subset of patients with HCV infection who have liver cirrhosis.
BACKGROUND: Sustained virological response (SVR) is achieved in a high proportion of patients with chronic hepatitis C infection, particularly those with genotype 2 or 3 HCV infection. However, data on long-term durability of virological response in patients who achieve SVR are limited. AIM: To evaluate the long-term durability of virological response in patients who have achieved SVR with interferon-based combination therapy. METHODS: One hundred patients with chronic HCV infection who had obtained SVR after IFN and ribavirin combination therapy were followed up for up to 8 years with annual HCV RNA testing. RESULTS: During a followed up of 6 months to 8 years, 8 of 100 patients with initial SVR developed late relapse of HCV infection. Relapse was more common in patients who had cirrhosis (5/28 [18%] vs. (3/72 [4%] with no cirrhosis; p=0.037). CONCLUSION: SVR is durable in most patients, but some patients do have late relapse; long term follow up may be particularly important in a subset of patients with HCV infection who have liver cirrhosis.
Authors: M Martinot; P Marcellin; N Boyer; J Detmer; M Pouteau; C Castelnau; C Degott; A Aupérin; M Collins; J Kolberg; J Wilber; J P Benhamou; S Erlinger Journal: Ann Intern Med Date: 1997-06-01 Impact factor: 25.391
Authors: E Formann; P Steindl-Munda; H Hofer; W Jessner; U Bergholz; C Gurguta; P Ferenci Journal: Aliment Pharmacol Ther Date: 2006-02-15 Impact factor: 8.171
Authors: Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie Journal: Hepatology Date: 2009-03 Impact factor: 17.425
Authors: John D Scott; Brian J McMahon; Dana Bruden; Daniel Sullivan; Chriss Homan; Carol Christensen; David R Gretch Journal: Clin Infect Dis Date: 2006-02-28 Impact factor: 9.079
Authors: Koji Hara; Maria M Rivera; Christopher Koh; Mary Demino; Sandra Page; Pothu Raju Nagabhyru; Barbara Rehermann; T Jake Liang; Jay H Hoofnagle; Theo Heller Journal: J Infect Dis Date: 2013-10-14 Impact factor: 5.226
Authors: Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Shiv K Sarin; Radha K Dhiman; Rakesh Aggarwal; Shivaram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoor; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Samir Shah; Praveen K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan Journal: J Clin Exp Hepatol Date: 2014-06-24
Authors: Mohamed A Mekky; Hani I Sayed; Mohamed O Abdelmalek; Medhat A Saleh; Osman A Osman; Heba A Osman; Khairy H Morsy; Helal F Hetta Journal: Infect Drug Resist Date: 2019-01-22 Impact factor: 4.003